Neuland Laboratories Ltd reported consolidated revenue of Rs 5.14 billion and net profit of Rs 968.5 million for the September quarter. The pharmaceutical API manufacturer maintains steady performance supported by expanding global regulatory approvals and continuous innovation in manufacturing capabilities.
Key Highlights
-
Consolidated revenue from operations at Rs 5.14 billion for Q2 FY26
-
Net profit recorded at Rs 968.5 million, reflecting steady earnings
-
Growth driven by strong demand in pharmaceutical intermediate and API markets
-
Company holds over 300 developed processes and 100 APIs with 990+ global regulatory filings
-
Continuous focus on expanding US FDA-compliant manufacturing facilities
-
Emphasis on R&D innovation to sustain competitive advantage
-
Global client base spans nearly 80 countries, enhancing export revenue
-
Maintains robust pipeline of new product approvals and filings
-
Positioned as a key player in the global pharmaceutical supply chain
Detailed Report
Neuland Laboratories Ltd, a leading pharmaceutical active pharmaceutical ingredient (API) manufacturer, has delivered a robust performance in the quarter ended September 2025. The company reported consolidated revenue of Rs 5.14 billion and net profit of Rs 968.5 million, highlighting operational stability and market growth.
With a broad portfolio of over 300 manufacturing processes and more than 100 APIs, Neuland Labs continuously expands its regulatory reach with over 990 regulatory filings worldwide, including 72 active US Drug Master Files.
During Q2, the company reinforced its position through investments in cGMP-compliant production facilities designed to meet stringent international quality standards. Its R&D-led approach ensures ongoing development of innovative products to meet evolving pharmaceutical industry needs.
Serving customers in nearly 80 countries, Neuland remains a critical supplier in the global pharmaceutical ecosystem, aiming to capture further expansion opportunities while maintaining stringent quality and compliance standards.
Sources: Neuland Laboratories Official, ScanX, Screener.in